| 다발성경화증에서 알렘투주맙 치료 |
|
오지영 |
|
건국대학교병원 |
| Alemtuzumab in the Treatment of Multiple Sclerosis |
|
Jeeyoung Oh |
|
Department of Neurology, Konkuk University Medical Center, Seoul, Korea |
|
|
| Abstract |
|
"Alemtuzumab is a humanized monoclonal antibody against CD52 and is recently approved for the second-line therapy of active relapse-remitting multiple sclerosis in Korea. Alemtuzumab leads to arapid and long-lasting depletion of peripheral T and B cells with repopulation of immune cell compositionresulting in the rebalancing of immune-tolerance network. However, it has a considerable adverseeffects including infusion associated reaction, infection, and secondary autoimmune diseaserequiring close and regular monitoring during and for 4 years after the final infusion cycle. This reviewwill provide a summary of mechanism of action, data from the pivotal clinical studies, and safetyprofiles of alemtuzumab. Journal of Multiple Sclerosis 7(2):49-54, 2016" |
| Key Words:
Alemtuzumab, CD52, Monoclonal antibody, Multiple sclerosis |
|
PDF Links
Download Citation
